Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.37 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.37 |
| ▸ | QPCT | Q16769 | 11/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12448089 | 0.81 | CPB2 (0.39) | ALPLPLAAQPCTALPGCYP1A2 | |
| SCHEMBL11914065 | 0.76 | CPB2 (0.32) | IRAK4 | |
| SCHEMBL24977412 | 0.75 | ALPL (0.37) | ALPLPLAAALPG | |
| SCHEMBL18948348 | 0.75 | — | — | |
| SCHEMBL20380128 | 0.73 | CCR1 (0.47) | TGFBR1TGFBR2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL28813542 | 0.72 | APAF1 (0.49) | ALPLPLAAALPGCYP1A2 | |
| Bromide SCHEMBL28926580 | 0.71 | — | — | |
| SCHEMBL27850201 | 0.71 | — | — | |
| SCHEMBL2969002 | 0.71 | — | — | |
| SCHEMBL10529956 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183933-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2017-09-14 | — | — | US | disclosed |
| US-9676759-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-06-13 | — | — | US | disclosed |
| US-20140038936-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-06 | — | — | US | disclosed |
| US-8466288-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038936-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | ALPL 2676/4885PLAA 1528/4885QPCT 2151/4885 |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | ALPL 2676/4885PLAA 1528/4885QPCT 2151/4885 |
| US-10183933-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | PIK3CD, PIK3CA, PIK3R5 | ALPL 2676/4885PLAA 1528/4885QPCT 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.